GlassScriptPhysician profile
Albert Humphrey
NPI 1770543621
$10,376.23
in general payments reported to CMS, 2019-2025
36 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,251 · 2020: $896 · 2021: $798 · 2022: $729 · 2023: $559 · 2024: $1,190 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,210.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,636.28 | 2019-2025 | Farxiga, Wainua, Airsupra |
| Novo Nordisk INC | $498.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $332.80 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $295.85 | 2019-2025 | |
| Abbott Laboratories | $252.37 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $220.77 | 2023-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $188.79 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $174.22 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.16 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $142.43 | 2019-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $139.85 | 2019-2023 | |
| Global Blood Therapeutics, INC. | $108.63 | 2020-2022 | |
| Amgen INC. | $100.26 | 2023-2025 | Repatha, Otezla, Krystexxa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $95.49 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $90.18 | 2020-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $73.20 | 2021-2023 | Onpattro |
| Abbvie INC. | $56.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.54 | 2020-2021 | |
| Cequr Corporation | $50.00 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $35.16 | 2021-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.79 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $34.63 | 2023-2025 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $26.29 | 2020-2022 | |
| Boston Scientific Corporation | $23.58 | 2024 | Spectra Wavewriter |
| Paratek Pharmaceuticals, INC. | $23.01 | 2025 | Nuzyra |
| Astellas Pharma US INC | $22.67 | 2025 | Veozah |
| Redhill Biopharma INC. | $22.41 | 2023 | |
| Seqirus USA INC | $19.85 | 2024 | Flucelvax, Fluad |
| Teva Pharmaceuticals USA, INC. | $19.01 | 2025 | Austedo Xr |
| Actelion Pharmaceuticals US, INC. | $18.68 | 2024 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $16.37 | 2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.63 | 2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $14.27 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $13.12 | 2024 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.